News & Media
Newsroom
SK Life Science Launches Its Second National Ad, Continuing to Lead with the Only Direct-toConsumer Commercial for an Anti-Seizure Drug in the U.S.
5.19.2025
Full Release
SK Life Science, Inc. to Showcase Important XCOPRI® (cenobamate tablets) CV Data on Responsive Neurostimulation Epileptiform Events at the 77th American
04.04.2025
Full Release
Newly Published Epilepsia Supplement Highlights Potential of Third Generation Antiseizure Medications to Help More Patients Achieve Seizure Freedom
3.20.2025
Full Release
Welcome to the news and information center for SK Life Science, Inc.
To learn more about SK Life Science, please download our corporate brochure
For more information about epilepsy, please download this infographic
For more information about Lennox-Gastaut syndrome, please download this fact sheet
SK Life Science at a Glance
Headquarters Location: Paramus, NJ
R&D Begins: 1993
Parent Company: SK Life Science is a subsidiary of SK Biopharmaceuticals, CO., LTD, and both are a part of SK Group
Number of Employees: 200+ Employees
Disease Category Focus: CNS Disorders and Oncology
Pipeline: 8 compounds under clinical development